| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000037267 |
| Receipt No. | R000042489 |
| Scientific Title | A study to evaluate effect of test food on whole body endurance improvement and fatigue inhibition. |
| Date of disclosure of the study information | 2019/07/12 |
| Last modified on | 2020/10/09 (Ver. 5) |
| Basic information | ||
| Public title | A study to evaluate effect of test food on whole body endurance improvement and fatigue inhibition. | |
| Acronym | A study to evaluate effect of test food on whole body endurance improvement and fatigue inhibition. | |
| Scientific Title | A study to evaluate effect of test food on whole body endurance improvement and fatigue inhibition. | |
| Scientific Title:Acronym | A study to evaluate effect of test food on whole body endurance improvement and fatigue inhibition. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To confirm effects caused by test food whole body endurance and fatigue feeling after exercise. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | *Maximum oxygen uptake
*Visual analog scale questionnaire on fatigue feeling |
| Key secondary outcomes | *Rate of perceived exertion
*Exercise performance *PWC@75%HRmax *Heart beat number on exercise *Blood biochemical parameters *IL-6 *Growth hormone *Glucagon *Free fatty acid *Microbiota of gut *Blood metabolome analysis *Muscle mass *Body fat mass *SF-8 questionnaire *Incidence rate of adverse events and side effects |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake four tablets of test food per one day for nine weeks. | |
| Interventions/Control_2 | Intake four tablets of test food per one day for nine weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1)Males aged 20-49 years at a time of obtaining informed consent.
2)Subjects who have exercise habits (over 30 minutes at once) once or twice a week. 3)Subjects who can continue with the exercise habits. 4)Subjects who don't take prohibited foods whthin one week before informed consent and can keep it during test period. 5)Subjects who show understanding of the clinical study procedures and agreement with participating this study by written informed consent. |
|||
| Key exclusion criteria | 1) Smokers except subjects who has not been smoking more than one year.
2) From the background questionnaire at preliminary test, subjects who defecate less than and equal to 5 times in a week, who have weakness in their digestive organ, and/or who easily have diarrhea. 3) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). 4) Subjects who have excessive alcohol intake. 5) Subjects who have extremely irregular dietary habits, have midnight work or irregular shift work. 6) Subjects who have allergy to medicines or foods. 7) Subjects who are participating the other clinical test, were participating it within the past 4 weeks, or are going to participate it. 8) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. 9) Subjects who donated over 400mL blood and/or blood components within the last three month to the current study. 10) Subjects who are going to be collected over 1200mL blood and/or blood components which is collected whithin the last 12 month and at this study 11) Subjects judged as unsuitable for the study by the principal or attending investigator. |
|||
| Target sample size | 90 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Division of Clinical Research | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Sanwauchikannda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Planning & Sales Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Sanwauchikanda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| Homepage URL | |||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Funding Source | |
| Organization | ASAHI QUALITY & INNOVATIONS, LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Sanwauchikannda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 90 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042489 |